Evidence map›Paper›PMID 40424415›Full record

ArticleInterdisciplinary cardiovascular and thoracic surgery2025

Impact of the number of involved lymph node zones on survival in stage IIIA-N2 lung adeno and squamous cell carcinoma.

Raffaella Griffo, Hans Hoffmann, Seyer Safi, Florian Eichhorn, Laura V Klotz, Thomas Muley, Philip Baum, Marc Kriegsmann, Helge Bischoff, Hauke Winter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raffaella GriffoDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.ORCID 0009-0006-2080-4606
Hans HoffmannDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Seyer SafiDivision of Thoracic Surgery, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
Florian EichhornDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Laura V KlotzDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Thomas MuleyTranslational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Philip BaumDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Marc KriegsmannDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Helge BischoffDepartment of Thoracic Oncology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Hauke WinterDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Martin E EichhornDepartment of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-0362-0374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe role of upfront surgery in treating stage IIIA-N2 non-small cell lung cancer remains controversial. This study aimed to evaluate the role of upfront surgery in selected patients with stage IIIA-N2 and assess the prognostic significance of the number of involved lymph node zones in relation to the N2-subclassification proposed by the International Association for the Study of Lung Cancer, comparing adenocarcinoma and squamous cell carcinoma.

methodsWe retrospectively analysed patients with pIIIA-N2 adeno- or squamous cell carcinoma who underwent complete surgical resection with zone-based lymph node dissection. Survival was calculated using the Kaplan-Meier method, and group differences were assessed via log-rank test and Cox regression analysis.

resultsA total of 222 patients were analysed. The 5-year overall survival rate was 43%, with a median overall survival of 47.2 months. In the adenocarcinoma cohort, the N2b-subgroup was associated with a 1.7-fold increased risk of death, whereas adjuvant chemotherapy reduced the risk by 41%. In squamous cell carcinoma, neither adjuvant chemotherapy nor the N2b-subgroup were identified as prognostic factors for overall survival.

conclusionsThe zone concept for intraoperatively assigning lymph nodes and the proposed N2-subgroups allowed a good stratification of long-term survival in patients with adenocarcinoma.

Indexed as

Adenocarcinoma of LungCarcinoma, Squamous CellLung NeoplasmsLymph Node ExcisionLymph NodesPneumonectomyAgedFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTime Factorslung cancerN2-lymph node metastasesstage IIIAupfront surgery

Identifiers

PMID40424415
PMCPMC12158154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.